<DOC>
	<DOCNO>NCT00255645</DOCNO>
	<brief_summary>This long-term safety follow-up study ass post-treatment safety , 12 24 month , patient type 2 diabetes participation phaseII/III study GALLANT , GALLEX ARMOR . In addition , select patient , include pre-defined laboratory clinical finding , 12-week post-treatment follow-up visit , include laboratory evaluation adverse event recording .</brief_summary>
	<brief_title>G-PLUS ( GALLANT , GALLEX ARMOR - Post Treatment Follow-up Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Provision write informed consent Men woman either complete least 6 month previous treatment study GALLANT , GALLEX ARMOR meet predefined laboratory clinical finding participation say study . Received openlabel treatment tesaglitazar ( since posttreatment study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>